CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2023

Mar 30, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2023-03-28

Reporting Person: GRANDE ALICIA (VP, Treasurer and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-28	Common stock, par value $0.001 per share	M	58216	$0.79	Acquired	108773	Direct
2023-03-28	Common stock, par value $0.001 per share	S	28216	$16.60	Disposed	80557	Direct
2023-03-28	Common stock, par value $0.001 per share	S	10000	$16.55	Disposed	70557	Direct
2023-03-28	Common stock, par value $0.001 per share	S	10000	$16.52	Disposed	60557	Direct
2023-03-28	Common stock, par value $0.001 per share	S	10000	$16.37	Disposed	50557	Direct
2023-03-29	Common stock, par value $0.001 per share	M	50000	$1.13	Acquired	100557	Direct
2023-03-29	Common stock, par value $0.001 per share	S	20000	$16.72	Disposed	80557	Direct
2023-03-29	Common stock, par value $0.001 per share	S	20000	$16.70	Disposed	60557	Direct
2023-03-29	Common stock, par value $0.001 per share	S	10000	$16.67	Disposed	50557	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-28	Options to purchase common stock	$0.79	M	58216	Disposed	2023-06-15	Common Stock (58216)	Direct
2023-03-29	Options to purchase common stock	$1.13	M	50000	Disposed	2024-01-03	Common Stock (50000)	Direct

Footnotes

F1: Shares were sold to cover exercise price of options, tax withholding requirements and for personal reasons. Shares were not sold as a result of any disagreement with the Company and Ms. Grande remains an officer of the Company.

F2: Options vested in two annual tranches beginning on June 15, 2017.

F3: Options vested in three annual tranches beginning on January 3, 2018.